History
A list of downloadable documents created during development.
Background information
-
-
Appendix A - RRP decision paper - August 2015
-
-
-
Appendix A - matrix of stakeholders
-
-
Appendix B - GE proposal paper - June 2015
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): equality impact assessment - guidance development
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): equality impact assessment - guidance development
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final appraisal determination
-
-
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): response to consultee, commentator and public comments on the ACD
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): consultee and commentator comments on the ACD
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Roche pharmaceuticals
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Breakthrough Breast Cancer
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Royal College of Nursing
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Royal College of Physicians
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Department of Health
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG addendum-recalculation of drug costs
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): appraisal consultation
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): appraisal consultation
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): evaluation report
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): pre-meeting briefing
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Evidence Review Group report
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Evidence Review Group report
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG report erratum
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Evidence Review Group report - factual accuracy check
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Roche
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Roche (PDF 3.05 MB)
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): clarification
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): NICE clarification letter
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): manufacturer response to the NICE clarification letter
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): NICE second clarification letter
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): manufacturer response to the second NICE clarification letter
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): patient group, professional group and NHS organisation submission statements
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Breakthrough Breast Cancer
-
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): joint submission from NCRI/Royal College of Physicians/RCR/ACP/JCCO
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): EIA - scoping
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): EIA - scoping
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): EIA - scoping (PDF 53 KB)
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final scope
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final scope
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final scope (PDF 38 KB)
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final matrix
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final matrix
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): final matrix (PDF 57 KB)
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): institute's response to consultee and commentator comments on the draft scope
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): institute's response to consultee and commentator comments on the draft scope
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Institute's response to consultee and commentator comments on the draft matrix
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): Institute's response to consultee and commentator comments on the draft matrix
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): draft scope
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): draft scope
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): draft scope (PDF 49 KB)
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): provisional matrix
-
Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): provisional matrix
-
Breast cancer (first line) - bevacizumab: final scope
-
Breast cancer (first line) - bevacizumab: final scope
-
Breast cancer (first line) - bevacizumab: final scope (PDF 28 KB)
Breast cancer (first line) - bevacizumab: final matrix of consultees and commentators
-
Breast cancer (first line) - bevacizumab: final matrix of consultees and commentators
-
Breast cancer (first line) - bevacizumab: final matrix of consultees and commentators (PDF 33 KB)
Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the draft scope
-
Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the draft scope
-
Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the provisional matrix
-
Breast cancer (first line) - bevacizumab: Institute's response to consultee and commentator comments on the provisional matrix
-
Breast cancer (first line) - bevacizumab: draft scope (for second consultation)
-
Breast cancer (first line) - bevacizumab: draft scope (for second consultation)
-
Breast cancer (first line) - bevacizumab: draft scope (for second consultation) (PDF 36 KB)
Breast cancer (first line) - bevacizumab: provisional matrix (for second consultation)
-
Breast cancer (first line) - bevacizumab: provisional matrix (for second consultation)
-
Breast cancer (first line) - bevacizumab: provisional matrix (PDF 44 KB)
Breast cancer (first line) - bevacizumab: draft scope
-
Breast cancer (first line) - bevacizumab: draft scope
-
Breast cancer (first line) - bevacizumab: draft scope (PDF 47 KB)
Breast cancer (first line) - bevacizumab: provisional matrix
-
Breast cancer (first line) - bevacizumab: provisional matrix
-
Breast cancer (first line) - bevacizumab: provisional matrix (PDF 44 KB)